Liver transplantation for erythropoietic protoporphyria liver disease
- 1 December 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 11 (12) , 1590-1596
- https://doi.org/10.1002/lt.20620
Abstract
In erythropoietic protoporphyria (EPP), there is excessive production of protoporphyrin, primarily in the bone marrow, resulting in increased biliary excretion of this heme precursor. Some patients will develop progressive liver disease that may ultimately require liver transplantation. However, excessive production of protoporphyrin by the bone marrow continues after transplantation, which may cause recurrent disease in the allograft. This study was performed to define post-transplant survival, the risk of recurrent disease, and specific management issues in patients transplanted for EPP liver disease. The patients studied consisted of twelve males and eight females, with an average age of 31 (range, 13–56) years at the time of transplantation. The estimated maximum MELD score prior to transplant was 21 (range, 15–29). Unique complications in the perioperative period were light induced tissue damage in four patients and neuropathy in six, requiring prolonged mechanical ventilation in four. Patient and graft survival rates were 85% at 1 year, 69% at 5 years, and 47% at 10 years. Recurrent EPP liver disease occurred in 11 of 17 patients (65%) who survived more than 2 months. Three patients were retransplanted at 1.8, 12.6, and 14.5 years after the initial transplant for recurrent EPP liver disease. In conclusion, the 5-year patient survival rate in patients transplanted for EPP liver disease is good, but the recurrence of EPP liver disease appears to diminish long term graft and patient survival. (Liver Transpl 2005;11:1590–1596.)Keywords
This publication has 33 references indexed in Scilit:
- Genotypic determinants of phenotype in North American patients with erythropoietic protoporphyriaMolecular Genetics and Metabolism, 2003
- The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECHNature Genetics, 2001
- Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyriaGastroenterology, 1999
- Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation.Journal of Clinical Investigation, 1998
- Erythropoietic protoporphyria: Unusual skin and neurological problems after liver transplantationGastroenterology, 1991
- Predictable and unpredictable hazards of erythropoietic protoporphyriaClinical and Experimental Dermatology, 1991
- Hepatobiliary implications and complications in protoporphyria, a 20-year studyClinical Biochemistry, 1989
- Hepatic and bile porphyrins in patients with protoporphyria and liver failureGastroenterology, 1988
- Inhibition of liver surface membrane Na+, K+-adenosine triphosphatase, Mg+2-adenosine triphosphatase and 5′- nucleotidase activities by protoporphyrinGastroenterology, 1983
- Protoporphyrin-induced Cholestasis in the Isolated In Situ Perfused Rat LiverJournal of Clinical Investigation, 1981